The new BIO-Norstella State of Emerging Biotech report finds venture capital has returned, pipelines are becoming more efficient, and emerging biotech companies continue to […]
BIO 2026: As capital returns, focus on quality over quantity Read More »
From drug discovery to target identification, biotech leaders explored where AI is delivering results today, why data quality matters, and how companies can successfully
BIO 2026: Where AI is delivering – and where biotech must go next Read More »
“AI systems will likely have a central role over the next several years in almost every component of the biotech ecosystem,” says Joe Franklin,
BIO 2026: What to know about the AI Summit Read More »
Patient advocates are praising Virginia Gov. Abigail Spanberger’s May 19 veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271), arguing
Patient groups praise Virginia PDAB veto Read More »
When BIO President & CEO John F. Crowley met INDY NXT racer James Roe at a Notre Dame game, something clicked. It wasn’t a
Patient advocacy drives innovation: James Roe’s asthma story comes to BIO 2026 Read More »
“We’re finding that the most disruptive pieces of legislation are much more likely to advance in state legislatures first, before eventually gaining traction at
State of play: BIO Coffee Chat covers how state policies impact access Read More »
Advancing innovation in the women’s health space has long been an uphill battle. But a number of leaders in the biotech community have taken
BIO panel at HERS explores women’s health biotech ecosystem Read More »
Patient advocacy is a driving force behind some of today’s most promising breakthroughs in biotechnology—where progress is increasingly powered by strong, productive collaboration between
BIO Coffee Chat explores venture philanthropy Read More »
“Biotechnology innovation is advancing at an unprecedented pace, delivering new treatments and cures that offer long-awaited hope to patients and their families,” said Karin
BIO Coffee Chat: Price controls like MFN harm access, increase costs Read More »
The inaugural BIO Investment and Growth (BIG) Summit was a chance for leaders in the biotech industry to catch up on domestic and international
BIG Summit themes: Resilient investment, MFN threat, patients in the center Read More »
